These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

445 related items for PubMed ID: 26093176

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Hyperkalemia associated with use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.
    Raebel MA.
    Cardiovasc Ther; 2012 Jun; 30(3):e156-66. PubMed ID: 21883995
    [Abstract] [Full Text] [Related]

  • 5. Advances in treatment of hyperkalemia in chronic kidney disease.
    Sarafidis PA, Georgianos PI, Bakris GL.
    Expert Opin Pharmacother; 2015 Jun; 16(14):2205-15. PubMed ID: 26330193
    [Abstract] [Full Text] [Related]

  • 6. Potassium homeostasis and renin-angiotensin-aldosterone system inhibitors.
    Weir MR, Rolfe M.
    Clin J Am Soc Nephrol; 2010 Mar; 5(3):531-48. PubMed ID: 20150448
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Updates on medical management of hyperkalemia.
    Lopes MB, Rocha PN, Pecoits-Filho R.
    Curr Opin Nephrol Hypertens; 2019 Sep; 28(5):417-423. PubMed ID: 31268919
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Prediction and management of hyperkalemia across the spectrum of chronic kidney disease.
    Lazich I, Bakris GL.
    Semin Nephrol; 2014 May; 34(3):333-9. PubMed ID: 25016403
    [Abstract] [Full Text] [Related]

  • 14. [Hyperkalemia - current therapuetic strategies].
    Głogowski T, Wojtaszek E.
    Wiad Lek; 2016 May; 69(5):745-748. PubMed ID: 28033600
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. [Renin-angiotensin-aldosterone system inhibitors and electrolyte disturbances].
    Kato H, Kobayashi K, Uchida S.
    Nihon Rinsho; 2012 Sep; 70(9):1536-41. PubMed ID: 23012800
    [Abstract] [Full Text] [Related]

  • 17. Hyperkalemia in patients undergoing hemodialysis: Its pathophysiology and management.
    Shibata S, Uchida S.
    Ther Apher Dial; 2022 Feb; 26(1):3-14. PubMed ID: 34378859
    [Abstract] [Full Text] [Related]

  • 18. Potassium-lowering agents for the treatment of nonemergent hyperkalemia: pharmacology, dosing and comparative efficacy.
    Bridgeman MB, Shah M, Foote E.
    Nephrol Dial Transplant; 2019 Dec 01; 34(Suppl 3):iii45-iii50. PubMed ID: 31800078
    [Abstract] [Full Text] [Related]

  • 19. Serum potassium in stage 5 CKD patients on their first presentation in a dialysis service of a county hospital in western Romania.
    Gluhovschi G, Mateş A, Gluhovschi C, Golea O, Gădălean F, Somai M, Ene I, Petrica L, Velciov S.
    Rom J Intern Med; 2014 Dec 01; 52(1):30-8. PubMed ID: 25000676
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.